Unknown

Dataset Information

0

Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.


ABSTRACT: Hematopoietic stem cells can be mobilized from healthy donors using single-agent plerixafor without granulocyte colony-stimulating factor and, following allogeneic transplantation, can result in sustained donor-derived hematopoiesis. However, when a single dose of plerixafor is administered at a conventional 240 ?g/kg dose, approximately one-third of donors will fail to mobilize the minimally acceptable dose of CD34+ cells needed for allogeneic transplantation. We conducted an open-label, randomized trial to assess the safety and activity of high-dose (480 ?g/kg) plerixafor in CD34+ cell mobilization in healthy donors. Subjects were randomly assigned to receive either a high dose or a conventional dose (240 ?g/kg) of plerixafor, given as a single subcutaneous injection, in a two-sequence, two-period, crossover design. Each treatment period was separated by a 2-week minimum washout period. The primary endpoint was the peak CD34+ count in the blood, with secondary endpoints of CD34+ cell area under the curve (AUC), CD34+ count at 24 hours, and time to peak CD34+ following the administration of plerixafor. We randomized 23 subjects to the two treatment sequences and 20 subjects received both doses of plerixafor. Peak CD34+ count in the blood was significantly increased (mean 32.2 versus 27.8 cells/?L, P=0.0009) and CD34+ cell AUC over 24 hours was significantly increased (mean 553 versus 446 h cells/?L, P<0.0001) following the administration of the 480 ?g/kg dose of plerixafor compared with the 240 ?g/kg dose. Remarkably, of seven subjects who mobilized poorly (peak CD34+ ?20 cells/?L) after the 240 ?g/kg dose of plerixafor, six achieved higher peak CD34+ cell numbers and all achieved higher CD34+ AUC over 24 hours after the 480 ?g/kg dose. No grade 3 or worse drug-related adverse events were observed. This study establishes that high-dose plerixafor can be safely administered in healthy donors and mobilizes greater numbers of CD34+ cells than conventional-dose plerixafor, which may improve CD34+ graft yields and reduce the number of apheresis procedures needed to collect sufficient stem cells for allogeneic transplantation. (ClinicalTrials.gov, identifier: NCT00322127).

SUBMITTER: Pantin J 

PROVIDER: S-EPMC5394957 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6436017 | BioStudies
2018-01-01 | S-EPMC6177648 | BioStudies
2018-01-01 | S-EPMC5927989 | BioStudies
2017-01-01 | S-EPMC5428459 | BioStudies
2020-01-01 | S-EPMC7452813 | BioStudies
1000-01-01 | S-EPMC3065558 | BioStudies
2016-01-01 | S-EPMC5500229 | BioStudies
2015-01-01 | S-EPMC4490031 | BioStudies
2017-01-01 | S-EPMC5515540 | BioStudies
2018-01-01 | S-EPMC6091693 | BioStudies